Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$8.6 - $11.9 $1,444 - $1,999
168 Added 2.07%
8,287 $83,000
Q4 2023

Feb 14, 2024

BUY
$7.76 - $10.29 $41,065 - $54,454
5,292 Added 187.19%
8,119 $81,000
Q3 2023

Nov 14, 2023

BUY
$9.14 - $24.62 $24,851 - $66,941
2,719 Added 2517.59%
2,827 $26,000
Q2 2023

Aug 14, 2023

SELL
$23.2 - $27.29 $171,633 - $201,891
-7,398 Reduced 98.56%
108 $2,000
Q1 2023

May 12, 2023

SELL
$22.26 - $30.85 $54,648 - $75,736
-2,455 Reduced 24.65%
7,506 $174,000
Q4 2022

Feb 14, 2023

BUY
$19.96 - $28.22 $97,963 - $138,503
4,908 Added 97.13%
9,961 $252,000
Q3 2022

Nov 14, 2022

BUY
$18.26 - $31.1 $42,290 - $72,027
2,316 Added 84.62%
5,053 $97,000
Q2 2022

Aug 15, 2022

BUY
$19.08 - $26.7 $52,221 - $73,077
2,737 New
2,737 $70,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $919M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track State Of Wyoming Portfolio

Follow State Of Wyoming and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.